
==== Front
Kidney Int Rep
Kidney Int Rep
Kidney International Reports
2468-0249
Elsevier

S2468-0249(24)01712-1
10.1016/j.ekir.2024.05.005
Review
The Role of Mitochondrial Dysfunction in CKD-Related Vascular Calcification: From Mechanisms to Therapeutics
Huang Junmin 1
Hao Junfeng 1
Wang Peng wangpeng@gdmu.edu.cn
1∗
Xu Yongzhi lxyzhi@126.com
1∗
1 Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
∗ Correspondence: Peng Wang or Yongzhi Xu, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China. wangpeng@gdmu.edu.cnlxyzhi@126.com
14 5 2024
9 2024
14 5 2024
9 9 25962607
27 2 2024
19 4 2024
6 5 2024
© 2024 International Society of Nephrology. Published by Elsevier Inc.
2024
International Society of Nephrology
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Vascular calcification (VC) is a common complication of chronic kidney disease (CKD) and is closely associated with cardiovascular events. The transdifferentiation of vascular smooth muscles (VSMCs) into an osteogenic phenotype is hypothesized to be the primary cause underlying VC. However, there is currently no effective clinical treatment for VC. Growing evidence suggests that mitochondrial dysfunction accelerates the osteogenic differentiation of VSMCs and VC via multiple mechanisms. Therefore, elucidating the relationship between the osteogenic differentiation of VSMCs and mitochondrial dysfunction may assist in improving VC-related adverse clinical outcomes in patients with CKD. This review aimed to summarize the role of mitochondrial biogenesis, mitochondrial dynamics, mitophagy, and metabolic reprogramming, as well as mitochondria-associated oxidative stress (OS) and senescence in VC in patients with CKD to offer valuable insights into the clinical treatment of VC.

Keywords

CKD
mitochondria
osteogenic transdifferentiation
vascular calcification
vascular smooth muscle cell
==== Body
pmcVC is associated with aging and various diseases and is especially prevalent in patients with diabetic nephropathy and CKD. Following the development of severe VC, vascular stiffness increases, and compliance concomitantly decreases, leading to a 3- to 4-fold increased risk of death and cardiovascular disease,1 which is the primary cause of mortality in patients with end-stage renal disease.2 In the context of end-stage renal disease, the pathological deposition of calcium salts in the arterial wall becomes extremely active. In addition, coronary artery calcification was observed to be independently and significantly correlated with the risk of myocardial infarction and heart failure in patients with CKD.3 Moreover, arterial calcification severely affects the long-term patency rate of arteriovenous fistulae.4 There is currently no unified consensus on how to delay or halt the calcification process in patients with CKD.

CKD-related calcification is hallmarked by medial calcification. VC is a long-term and controllable active pathological process.5 The recognized mechanisms underlying calcification involve calcium and phosphorus disorders, lower levels of calcification inhibitors, osteogenic differentiation of VSMCs, cell apoptosis, and reorganization of vascular extracellular matrix. Unlike other smooth muscle cells, VSMCs do not undergo terminal differentiation and exhibit significant plasticity.6 Their osteogenic transformation serves as the pathophysiological basis of VC in CKD. Under sustained stimuli such as mineral disorders and uremic toxins, the expression of contractile markers is down-regulated in VSMCs, whereas that of osteogenic markers, including bone morphogenetic protein 2 (BMP2) and runt-related transcription factor 2 (RUNX2), is upregulated.7,8 The transcriptional activation of osteogenic genes in vascular cells plays a crucial role in VC in CKD.

Mitochondria are key cellular energy factories that synthesize adenosine triphosphate (ATP) and various metabolic substrates in the oxidative respiratory chain. Reactive oxygen species (ROS) is a by-product of the respiratory activity of the electron transport chain and plays an instrumental role in different aspects as a key signaling molecule.9, 10, 11 Mitochondrial homeostasis is comaintained by mitochondrial biogenesis, fission, and fusion, and mitophagy. As energy-intensive cells, VSMCs are susceptible to the influence of mitochondrial morphology and dysfunction. It is worthwhile noting that mitochondria are not only an important source but also a target of uremic toxins.12 The accumulation of uremic toxins, including proinflammatory cytokines and ROS, stimulates the osteogenic differentiation of VSMCs through different downstream pathways, with mitochondrial dysfunction serving as a central mediator.13

Although the exact mechanism of VC in CKD remains elusive, mounting evidence indicates that mitochondrial dysfunction and metabolic reprogramming are key factors that are implicated in VC in CKD and induce the transformation of VSMCs into an osteogenic phenotype.14, 15, 16 To identify the significance of mitochondrial dysfunction in VSMCs osteogenic differentiation in VC in CKD, this article aimed to outline recent advancements in related fields and explore potential clinical treatments for improving VC outcomes in patients with CKD.

Mitochondrial Biogenesis in VC

As a dynamic organelle, mitochondrial biogenesis is a regenerative program that maintains mitochondrial numbers, replacing old and damaged mitochondria with new and healthy ones to meet cellular energy needs. This process is largely dependent on the regulation of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α). PGC-1α predominantly activates 2 key nuclear transcription factors, namely nuclear factor E2-related factor 1 and nuclear factor E2-related factor 2, which in turn trigger the transcription of the oxidative phosphorylation system protein encoded by mitochondrial transcription factor A and nuclear DNA.17 Meanwhile, mitochondrial transcription factor A is responsible for governing the transcription and replication of mitochondrial DNA, with the oxidative phosphorylation system protein being an integral component of the oxidative respiratory chain. Multiple pathways such as cGMP, AMP-activated protein kinase (AMPK), and sirtuin (SIRT) 1 have been established to regulate the expression of PGC-1α.18 Previous studies demonstrated that under high phosphate-simulated uremia conditions, the former collaborates with laminar shear forces to induce mitochondrial biogenesis, initiating the osteogenic transformation of VSMCs through the integrin β1-ERK1/2 signaling pathway, as evidenced by the upregulation of mitochondrial transcription factor A and mitochondrial DNA polymerase γ.14 However, inhibition of PGC-1α expression weakens the maximum respiratory capacity of mitochondria, thereby enhancing the production of superoxide and mitochondrial ROS. In turn, this promotes the expression of RUNX2 and sex determining region Y-box 9 and the osteogenic transdifferentiation of VSMCs, ultimately driving VC.16 The rationale behind this phenomenon may be ascribed to increased energy demands during the phenotype transformation process of VSMCs, inducing an initial increase in compensatory mitochondrial biogenesis.19 For example, PGC-1α expression is upregulated in VSMCs and activates mitochondrial biogenesis as a response to early hypoxic damage.20

Indeed, restoration of mitochondrial biogenesis is effective against VC. According to a previous study, metformin promotes PGC-1α expression and downregulates the expression of 2 osteogenic gene markers (RUNX2 and BMP2) in β-glycerophosphate (β-GP)-treated VSMCs in a dose-dependent manner. Mechanistically, metformin interferes with the activation of β-GP-induced apoptotic gene pyruvate dehydrogenase kinase 4 (PDK4) through the AMPK-PGC-1α signaling pathway.21 In VSMCs, PDK4 expression was found to be upregulated in the Pi-induced calcification model. As a downstream factor, SIRT3 mediates the effects of PGC-1α in inhibiting mitochondrial ROS production and calcium deposition by deacetylating superoxide dismutase 2, a major antioxidant in mitochondria.16,22 In the future, the PGC-1α/ SIRT3 pathway may be a target for optimizing the osteogenic transformation of VSMCs. In addition, resveratrol supplementation has been shown to attenuate VC, possibly mediated by upregulation of mitochondrial biogenesis via the AMPK or SIRT 1/Nrf2 signaling pathway.23 Overall, the aforementioned in vivo and in vitro experiments established that PGC-1α overexpression can inhibit osteogenic transformation in VSMCs and subsequently attenuate VC, indicating that it is a powerful endogenous protective agent against calcification (Figure 1).Figure 1 Mitochondrial biogenesis with PGC-1α as the regulatory center is highly involved in the osteogenic transdifferentiation of VSMCs through apoptosis, mitochondrial dynamics, cell autophagy, etc., (Created with BioRender.com).

PGC-1α, peroxisome proliferator-activated receptor gamma coactivator-1α; VSMCs, vascular smooth muscles.

Mitochondrial Dynamics in VC

Mitochondrial dynamics include mitochondrial division and fusion, and their balance plays a vital role in the role and form of mitochondria. They participate in meeting cellular-specific energy demands and responding to external signals.24 In mammalian cells, mitochondrial fusion is coregulated by outer mitochondrial membrane proteins and inner mitochondrial membrane proteins, the former comprising mitofusin 1 and mitofusin 2; whereas the latter, optic nerve atrophy factor 1, catalyzes mitochondrial inner fusion.25

Fission is largely carried out by dynamin-related protein 1 (DRP1) and fission protein 1, with calcineurin dephosphorylates DRP1 recruiting it to the mitochondrial surface to interact with mitochondrial fission factor, thereby promoting fission.26 As is well documented, mitochondrial fission is the foundation of early cell apoptosis. Pore-forming protein and DRP1 are colocated at the fission site and are implicated in ridge remodeling.27 The cytochrome c in mitochondria is redistributed from the cristae to the membrane gap and released into the cytoplasm, triggering the sequential activation of the caspase-9 and -3 cascades.28 Pathological stimuli elicit excessive mitochondrial division in VSMCs, generating a large amount of mitochondrial debris and ROS that eventually facilitate apoptosis.29 Lipoic acid prevents OS-induced VC by inhibiting VSMC apoptosis and restoring the Gas6/Axl/Akt survival pathway.30

Mitochondrial dynamics disorders are intricately linked to VC. DRP1 is enriched in calcified regions of human carotid arteries and has been found to exacerbate VC in an OS-dependent manner.31 A previous study determined that p53 aids in transferring DRP1 from the cytoplasm to mitochondria to promote fission and effectively inhibit the expression of mitophagy protein, BCL2-interacting protein 3, which may contribute to the osteogenic transformation of VSMCs and ultimately VC.32,33 Lactic acid upregulates DRP1-mediated mitochondrial fission and suppresses BCL2-interacting protein 3-induced mitophagy through the DNA-PKca/p53 pathway by activating nuclear receptor 4A1, significantly increasing the transcription of RUNX2 and BMP2 proteins in calcified VSMCs.34 Eliminating damaged mitochondria through a fission-dependent autophagy pathway is manifested by AMPK phosphorylating the DRP1 receptor mitochondrial fission factor to support mitochondrial autophagy.35 In the absence of sufficient energy, AMPK activates DRP1 phosphorylation and translocation to induce mitochondrial division and maximize ATP production.36 However, other studies have concluded that AMPK essentially serves as an upstream negative regulator for DRP1. AMPK reduces DRP1-mediated mitochondrial division, ultimately down-regulating the expression level of RUNX2 in VSMCs. Inhibition of AMPK phosphorylation mitigates the protective effect against VC.15,37

The effect of mitochondrial fusion on VC contrasts with that of DRP1-driven mitochondrial fission; that is, the activation of optic nerve atrophy factor 1 can delay the occurrence of calcification. Melatonin promotes mitochondrial fusion through the AMPK/optic nerve atrophy factor 1pathway, significantly reducing phosphate-induced calcium deposition, as well as the expression of alkaline phosphatase and RUNX2. Conversely, the removal of optic nerve atrophy factor 1 attenuates the protective effect of melatonin against VC.38 The mechanism underlying the effects of mitochondrial division and fusion on the osteogenic phenotype of VSMCs warrants further investigation. (Figure 2).Figure 2 DRP1-driven mitochondrial division promotes the osteogenic transdifferentiation of VSMCs and is regulated by melatonin, lactic acid, etc., whereas mitochondrial fusion exerts a protective role against VC (Created with BioRender.com).

DRP1, dynamin-related protein 1; VC, vascular calcification; VSMCs, vascular smooth muscles.

Mitophagy in VC

Mitophagy is a mechanism that plays a key role in maintaining mitochondrial mass. When damaged mitochondria cannot be cleared by autophagy, the resulting ROS storm eventually leads to programmed cell death. Mitophagy is a type of selective autophagy that reuses amino acids and fatty acids through successive steps.39 At present, its mechanisms can be divided into 2 categories, namely the ubiquitin-dependent pathways and nonubiquitin-dependent pathways. The ubiquitin-dependent pathway that has been extensively explored is the PTEN-induced putative kinase 1/Parkin pathway. Following mitochondrial damage, the membrane potential decreases, and PTEN-induced putative kinase 1, which was originally transferred to inner mitochondrial membrane and rapidly decomposed, stably accumulates on the outer mitochondrial membrane, thereby recruiting and activating Parkin. Moreover, mitofusin 2 is phosphorylated by PTEN-induced putative kinase 1 and acts as the receptor for Parkin in mitochondria.40 Afterward, the activated Parkin ubiquitinates proteins on mitochondria, facilitating the recruitment of p62 (a bridging protein that binds ubiquitin to LC3). This interaction leads to the clearance of damaged mitochondria by autophagy, occurring at the intersection of mitochondria and the endoplasmic reticulum.41 There are numerous LC3-interacting region-containing proteins on the outer mitochondrial membrane, including the NIX and BCL2-interacting protein 3 receptors that act as autophagy receptors to directly bind to LC3 without ubiquitination to initiate mitophagy.42,43

Notably, mitophagy plays a central role in VC by protecting VSMCs from OS and senescence. CKD progression results in impaired gluconeogenic function, accompanied by a decrease in glucose production and lactate clearance.44 As the product of glycolysis, lactate has been reported to assist in expediting the osteogenic transformation of VSMCs and VC by disrupting mitochondrial mass34 with poly (ADP-ribose) polymerase 1/DNA polymerase γ signaling mediating the above-mentioned effects, which in turn leads to the compensatory upregulation of mitochondrial uncoupling protein 2 and inhibition of mitophagy. Knockout of uncoupling protein 2 in VSMCs down-regulates the mRNA expression of lactate-induced RUNX2 and BMP2 and represses DRP1-mediated mitochondrial fission in VSMCs, ultimately alleviating calcification.45 Importantly, mitochondrial fission is closely related to mitophagy. Following a reduction in mitochondrial membrane potential, mitophagy is triggered by promoting mitochondrial separation and early contact between mitochondria and lysosomes.46 During mitophagy, Parkin simultaneously ubiquitinates PARIS and promotes the activity of PGC-1, a transcription factor, resulting in crosstalk with mitochondrial biogenesis.47 Furthermore, the expression of BCL2-interacting protein 3 is inhibited by the lactate/nuclear receptor 4A1/DNA-PKca/p53 axis, attenuating mitophagy and subsequently accelerating the progression of VC.48 Distinct from the dual effects of autophagy, the activation of mitophagy in existent cells protects against VC, and the increase in mitophagy flux attenuates apoptosis. In order to delay the onset of VC, further evidence is necessitated to identify upstream factors that modulate VSMC mitophagy49 (Figure 3).Figure 3 Mitophagy and mitochondrial biogenesis preserve mitochondrial mass and protect against cellular damage. Lactic acid exerts a strong promoting effect on the osteogenic differentiation of VSMCs by interfering with mitophagy, including both ubiquitin-dependent and non-ubiquitin-dependent pathways (Created with BioRender.com).

VSMCs, vascular smooth muscles.

Metabolic Reprogramming in VC

It is widely recognized that even under physiological conditions, VSMCs exhibit high levels of aerobic glycolysis and lactate production, similar to the Warburg effect in cancer cells.7 Glycolysis generates ATP by converting glucose to pyruvate, and approximately 45% of the ATP supply in VSMCs is derived from aerobic glycolysis.50 However, the preference of VSMCs for the less ATP-efficient metabolic mode of glycolysis remains unclear. It was previously thought that VSMCs may respond to greater energy demands by relying on rapid ATP supply, such as glycolytic reserve capacity.51 Nonetheless, a growing number of studies suggest that mitochondrial glycolysis is involved in regulating phenotypic transitions in VSMCs, particularly during VC.52

Glycolytic flux is tightly controlled by PFKFB. Noteworthily, the knockdown of PFKFB3 significantly inhibited the expression of osteoblast markers such as alkaline phosphatase l and osteocalcin in VSMCs. PFKFB3-mediated glycolysis promotes the osteogenic transdifferentiation of VSMCs by regulating FoxO3 expression and lactate production.53 Periosteal proteins exert their effects by inhibiting mitochondrial oxidative phosphorylation and hyperactivating glycolysis, as well as promoting β-catenin expression and down-regulating PPARc protein levels in vivo and in vitro to contribute to the development of VC. When blocked with hexokinase inhibitors, the calcification of VSMCs was significantly inhibited.54 Furthermore, the Wnt/β-catenin signaling pathway simultaneously mediates the effect of osteocalcin in the pathology of arterial calcification, contingent upon a reduction in maximal mitochondrial respiratory capacity, including a significant decrease in glycolytic capacity and reserve.55 As a promoter of glycolysis, PDK4 promotes the osteogenic transdifferentiation of VSMCs by phosphorylating SMAD1/5/8 and enhancing BMP2 signaling.56 Conversely, PDK4 promotes mitochondrial fragmentation, impairs mitochondrial respiratory capacity, and drives the metabolic reprogramming of VSMCs toward the Warburg effect. Interestingly, inhibition of glycolysis by 2-DG accelerates calcium deposition in VSMCs despite reducing β-GP-induced lactate production.57 As can be deduced, enhanced glycolysis may be an adaptive or protective mechanism for the calcification of VSMCs against energy depletion or OS induced by pathogenic factors. Other studies also concluded that reduced mitochondrial phosphorylation precedes a declined glycolytic capacity under pathological conditions.55

In CKD, hyperphosphatemia is an integral pathological factor promoting VC.58 Unexpectedly, the rates of glycolysis and ATP production are not altered in VSMCs exposed to β-GP. Instead, VSMCs have a higher oxidative phenotype, suggesting an increased respiratory reserve capacity.59 Discrepancies between studies may be ascribed to the cell type and the medium used; osteogenic differentiation of VSMCs induced by osteogenic and calcium phosphate media is mediated by different mechanisms, considering the substantial differences in the transcriptomic datasets regulating calcification genes and inconsistencies in mitochondrial energy metabolism alterations.51 In addition, even identical smooth muscle cells from different vascular beds exhibit different calcification tendencies.60 A study proposed similar conclusions, that is, oxidative phosphorylation system expression is upregulated in high phosphate-treated VSMCs, but the rates of glycolysis and lactate production remain unchanged.61

Although perspectives diverge, (i) glucose has been recognized as a major energy substrate for VSMCs, with VSMCs exhibiting enhanced glucose uptake and metabolism upon phenotypic transition; (ii) aberrant mitochondrial metabolic signaling is involved in the progression of calcification, whereas upregulation of mitochondrial oxidative phosphorylation system in CKD promotes the osteogenic transdifferentiation of VSMCs. Notwithstanding, the following remains to be elucidated: (i) the effect of glycolysis in VC across various disease backgrounds and (ii) the underlying mechanism by which phosphate causes mitochondrial dysfunction in VSMCs. In addition, it is important to acknowledge that endothelial cells and extracellular matrix play an important role in the osteogenic differentiation of VSMCs.62,63 It is challenging to account for all interactions in in vitro cell culture models, necessitating further validation through in vivo studies.

OS in VC

Oxidative phosphorylation of mitochondria and glycolysis are the 2 major intracellular ATP-generating pathways. Oxidative phosphorylation is mostly accomplished through the mitochondrial-electron transport chain,64 which generates approximately 90% of intracellular ROS.65 β-GP inhibits mitochondrial respiration and promotes OS by inhibiting complex I and complex III of the oxidative respiratory chain in VSMCs,66 whereas complex I is the primary source of mitochondrial ROS, ascribed to a reduction in mitochondrial proton and electron leakage and coupling efficiency.67

ROS accumulation can occur during the early stage of CKD and aggravates renal damage.68 Patients with advanced CKD experience an excessive ROS status due to excessive endotoxin, loss of antioxidants during dialysis, and complement and inflammatory cell activation.69 OS is caused by an increase in the production of ROS and plays a central role in the pathological mechanism underlying CKD-related VC.70,71 In particular, the uremic environment triggers vascular OS, which is a key event leading to catastrophic mineral ion influx into the VSMC layer and is closely related to the osteogenic reprogramming of VSMCs.72

In CKD, calcium phosphate is eventually converted to insoluble hydroxyapatite, which acts as the cornerstone of calcified vessels and stimulates the osteogenic transformation of VSMCs in a concentration-dependent manner. During this process, the decrease in mitochondrial membrane potential and the concurrent increase in intracellular ROS levels, coupled with the normal membrane potential, is a prerequisite for oxidative phosphorylation, establishing a positive feedback loop that promotes OS.73 Mitochondrial membrane depolarization, subsequent Ca2+ overload, and ERK1/2 activation pathway may mediate the excessive Pi-induced OS-related osteogenic differentiation of VSMCs.74 Studies have consistently documented that high Pi increases PiC abundance through the ERK1/2-mTOR signaling pathway and that silencing mitochondrial phosphate transport genes can relieve the high Pi-induced reduction in ROS production and calcification.75 PiC is the primary route for Pi entry into mitochondria, which is simultaneously associated with ATP generation and the opening of the PT pore. Therefore, its pathophysiological role in VC requires further exploration.76 When supplemented with NAC and mitochondrial complex I inhibitors, a reduction in mitochondrial ROS levels and a reversal of hypoxia-induced upregulation of osteogenic genes RUNX2, SOX9, and osteocalcin were observed.77 OS damage is the core issue caused by mitochondrial dysfunction, and existing evidence suggests that mitochondrial antioxidants are a promising option for the treatment of VC. However, targeted antioxidants have not yielded satisfactory results in translational medicine. Some scholars postulate that different organelles have inconsistent redox statuses and undergo dynamic changes, highlighting the need for precise antioxidant therapies.78 At the same time, there is evidence indicating that mitochondrial-derived peroxides cannot directly damage the DNA of chromatin. Nonetheless, targeting mitochondrial oxidation to VC holds promise for future applications.

Cellular Senescence During VC

Cellular senescence is a state of irreversible cell cycle arrest, accompanied by an increased expression of aging-related proteins, such as P53, P21, P16, and β-Gal. It is stimulated by various stress conditions, including elevated ROS levels, inflammatory factors, calcium and phosphorus metabolic disorders, and hyperglycemia.79 A persistent inflammatory microenvironment and premature senescence are biomarkers of the uremic phenotype. The specific secretory phenotype of senescent cells contributes to the physiological and pathological consequences in organisms, possibly by expelling chemical mediators, thereby further spreading OS and inflammatory phenotypes to adjacent cells.80 Damaged organelles and accumulation of abnormal proteins during cellular aging affect mitochondria, and in turn, mitochondrial dysfunction promotes cellular senescence.10 Mitochondrial dysfunction has been linked to the senescence of VSMCs. Indeed, senescent VSMCs tend to acquire an osteogenic phenotype, as evidenced by significant upregulation in alkaline phosphatase and RUNX2 expression.81, 82, 83

Circulating Klotho levels are often decreased in CKD, and Klotho deficiency is a model of premature aging. Klotho has been shown to maintain VSMC phenotype by regulating mitochondrial metabolic patterns.84 It is critical to further investigate the protective effect of Klotho on mitochondria against VC. In addition, in premature aging mouse models, the reduced accumulation of pyrophosphate due to aberrant mitochondrial function and reduced ATP utilization in VSMC cells eventually leads to excessive VC.85 Senescence may act as a mediator of CKD and is an important risk factor for CKD-related VC. The expression of the senescence marker P53 is upregulated in calcified VSMCs. Besides, previous studies have demonstrated that P53 promotes mitochondrial elongation and cellular senescence through DRP1 phosphorylation.33 Telomere loss activates P53 and inhibits PGC-1α, ultimately affecting mitochondrial biogenesis and respiratory function, thereby linking mitochondrial function to cellular senescence.86

Several studies support the theory that VSMC senescence leads to vascular lesions such as calcification, with VC serving as a marker of vascular stiffness and senescence.23 Exosomes secreted by endothelial cells promote VSMC senescence and osteogenic transdifferentiation by inducing a decrease in VSMC mitochondrial membrane potential and functional protein expression.87 Recent research indicates that GATA binding protein 6 may be an important regulator in VSMC senescence and osteogenic differentiation. GATA binding protein 6 is upregulated in the calcified aorta of mice and accelerates the osteogenic transdifferentiation of VSMCs by interfering with DNA repair. More importantly, SIRT6 represses GATA binding protein 6 transcription through deacetylation and then protects mice against arterial senescence and calcification.88 The specific mechanisms by which CKD-related aging leads to VC remain enigmatic.

Mitochondria-Targeted Therapy

Although VSMC differentiation represents a response to injury-induced changes, nonreversible VC may occur even during the early stages of kidney disease.89 VSMC transdifferentiation is a pivotal step in VC. Currently, there are no effective therapies that specifically target the regression of vascular or valvular calcification. In addition, an increasing number of studies are limited to animal or cellular experiments, and there is a paucity of convincing, controlled, and relevant clinical studies.90 Given the compromised metabolic ability of patients with CKD, nonnegligible biological toxicity and dialysis compatibility of drugs should be considered. Although preliminary results from the ongoing clinical cohort studies of VC in patients with CKD are not satisfactory, treatment with sodium thiosulfate appears to be the most promising.91 A meta-analysis further shows the effectiveness of sodium thiosulfate in delaying VC and atherosclerosis in hemodialysis patients.92 Recently, in order to more effectively inhibit osteogenic phenotype transformation of VSMCs, a biomimetic nanocarrier has been developed to precisely deliver sodium thiosulfate to VSMCs.93 At present, the protective effect of sodium thiosulfate on brain cells in CKD model is proved to be related to improvement of mitochondrial function.94 However, the therapeutic effect of sodium thiosulfate on VSMCs is still unclear. Therefore, it is necessary to further verify whether the protective effect of sodium thiosulfate on VC is achieved by targeting mitochondrial function.

There is limited relevant research exploring the role of mitochondrial function on VC in patients with CKD. Nevertheless, in vivo, and in vitro findings support the idea that therapeutic approaches to maintain mitochondrial homeostasis may be beneficial in ameliorating VC in the mouse CKD model. Recently, restoration of miR-30b was observed to attenuate aortic calcification in 5 of 6 nephrectomized rats, which may be mediated by down-regulation of SOX9 expression, preservation of mitochondrial MMP, and enhanced mitophagy pathway activation.95 In addition, novel insights into the pathology of uremia-induced VC have been reported. Carbamylation of ATP synthase subunits α and β in mitochondria leads to MMP alterations and dysfunction, inducing OS and inhibiting the expression of ectonucleotide pyrophosphate/phosphodiesterase 1 in VSMCs, and ultimately aggravating arterial calcification. These effects were alleviated following the administration of mitochondrial oxidants.96 Not only antimitochondrial oxidators but also interventions targeting mitochondrial biogenesis, inhibition of mitochondrial fission, restoration of mitophagy, and modulation of mitochondrial DNA effectively relieved VC in CKD models. Consequently, the relevant potential interventions were listed in this study. Despite our limited understanding of alterations in mitochondrial function in CKD-related VC, given that mitochondrial dysfunction is a common causative factor, the context listed in this table was not limited to CKD97, 98, 99, 100, 101 (Table 1).Table 1 Potential interventions targeting mitochondrial function for the treatment of calcification

Agents	Cellular	Animals	Mitochondrial function-related	Signaling Pathway	Target molecule	Osteogenic gene- phenotype	Vascular calcification	Reference	
Biogenesis	Mitochondrial dynamics	mitophagy	Metabolic reprogramming	Oxidative stress	Senescence	
Irisin	√	√			√		√			SIRT3	Runx2,Col1,Opn,Ocn	↓	15	
PGC-1α	√	√	√					√		SIRT3, SOD	Runx2,OPN,Sox9	↓	16	
Metformin	√		√		√		√			PDK4,AMPK	Runx2,BGP BMP-2		21	
α-Lipoic acid	√					√	√		Gas6 / Axl / Akt			↓	30	
Melatonin	√			√			√		AMPK/Drp1	Cas-pase 3	ALP,Runx2	↓	37	
Melatonin	√			√	√		√		AMPK/OPA1	Cas-pase 3	ALP,Runx2	↓	38	
Insulin-like growth factor I	√				√			√	Nrf2/Sirt3,p16/p21	PINK1			97	
Estrogen	√	√			√				SIRT1/LKB1/AMPK/Ulk1	Rab9			98	
MitoQ	√	√					√		Keap1/Nrf2	Bcl-2,Bax		↓	99	
Intermedin	√						√		AMPK/ SIRT3	SOD2	Runx2,BMP2	↓	100	
Ecklonia cava	√		√	√	√		√		PGC-1α/NRF2/SIRT3		Runx2,OCN	↓	101	

However, CKD-related VC develops from a complex and evolving pathogenesis, and it is not practical to restore or reverse it by targeting a single factor. Some scholars posit that actively addressing the ultimate shared pathway of calcification may be a future direction102 In summary, mitochondrial dysfunction has been established as a major cause of vascular calcium deposition. Consequently, this article focuses on the influence of mitochondrial homeostasis, metabolic recoding, ROS, and cellular senescence on the osteogenic phenotype of VSMCs. Nevertheless, further exploration and validation are required to determine the applicability of these novel findings in the clinical treatment of VC.

Disclosure

All the authors declared no competing interests.

Acknowledgments

We thank the Home for Researchers editorial team (www.home-for-researchers.com) for language editing service. This work was supported by grants from the 10.13039/501100001809 National Natural Science Foundation of China (82000651 and 8210691 ), the 10.13039/501100021171 Guangdong Basic and Applied Basic Research Foundation (2022A1515012209 ), the Zhanjiang Science and Technology Plan Project (2022A01160), the Research Start-up Funds for High-level Talents in the Affiliated Hospital of Guangdong Medical University (GCC2022046 and GCC2022038), the Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Noncommunicable Diseases (2022B1212030003), and the National Clinical Key Specialty Construction Project (Institute of Nephrology, Affiliated Hospital of Guangdong Medical University).

Author Contributions

JMH, PW, and YZX conceived and designed the overall study. JMH prepared figures and drafted the manuscript. J-FH performed a systematic literature search and prepared figures. All the authors revised the manuscript critically and approved the final version of the manuscript.
==== Refs
References

1 Rennenberg R.J. Kessels A.G. Schurgers L.J. van Engelshoven J.M. de Leeuw P.W. Kroon A.A. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis Vasc Health Risk Manag 5 2009 185 197 10.2147/vhrm.s4822 19436645
2 Lorenz G. Steubl D. Kemmner S. Worsening calcification propensity precedes all-cause and cardiovascular mortality in haemodialyzed patients Sci Rep 7 2017 13368 10.1038/s41598-017-12859-6
3 Chen J. Budoff M.J. Reilly M.P. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease JAMA Cardiol 2 2017 635 643 10.1001/jamacardio.2017.0363 28329057
4 Choi S.J. Yoon H.E. Kim Y.S. Pre-existing arterial micro-calcification predicts primary unassisted arteriovenous fistula failure in incident hemodialysis patients Semin Dial 28 2015 665 669 10.1111/sdi.12365 25787294
5 Quaglino D. Boraldi F. Lofaro F.D. The biology of vascular calcification Int Rev Cell Mol Biol 354 2020 261 353 10.1016/bs.ircmb.2020.02.007 32475476
6 Liu R. Leslie K.L. Martin K.A. Epigenetic regulation of smooth muscle cell plasticity Biochim Biophys Acta 1849 2015 448 453 10.1016/j.bbagrm.2014.06.004 24937434
7 Cao G. Xuan X. Hu J. Zhang R. Jin H. Dong H. How vascular smooth muscle cell phenotype switching contributes to vascular disease Cell Commun Signal 20 2022 180 10.1186/s12964-022-00993-2 36411459
8 Shanahan C.M. Crouthamel M.H. Kapustin A. Giachelli C.M. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate Circ Res 109 2011 697 711 10.1161/CIRCRESAHA.110.234914 21885837
9 Luo Y. Ma J. Lu W. The significance of mitochondrial dysfunction in cancer Int J Mol Sci 21 2020 5598 10.3390/ijms21165598 32764295
10 Miwa S. Kashyap S. Chini E. von Zglinicki T. Mitochondrial dysfunction in cell senescence and aging J Clin Invest 132 2022 e158447 10.1172/JCI158447
11 Garza-Lombó C. Pappa A. Panayiotidis M.I. Franco R. Redox homeostasis, oxidative stress and mitophagy Mitochondrion 51 2020 105 117 10.1016/j.mito.2020.01.002 31972372
12 Popkov V.A. Silachev D.N. Zalevsky A.O. Zorov D.B. Plotnikov E.Y. Mitochondria as a source and a target for uremic toxins Int J Mol Sci 20 2019 3094 10.3390/ijms20123094 31242575
13 Kyriakidis N.C. Cobo G. Dai L. Lindholm B. Stenvinkel P. Role of uremic toxins in early vascular ageing and calcification Toxins (Basel) 13 2021 26 10.3390/toxins13010026 33401534
14 Yang C.Y. Chang P.Y. Wu B.S. Tarng D.C. Lee O.K.S. Mechanical and chemical cues synergistically promote human venous smooth muscle cell osteogenesis through integrin β1-ERK1/2 signaling: a cell model of hemodialysis fistula calcification FASEB J 35 2021 e22042 10.1096/fj.202101064RR
15 Wang P.W. Pang Q. Zhou T. Irisin alleviates vascular calcification by inhibiting VSMC osteoblastic transformation and mitochondria dysfunction via AMPK/Drp1 signaling pathway in chronic kidney disease Atherosclerosis 346 2022 36 45 10.1016/j.atherosclerosis.2022.02.007 35255258
16 Feng H. Wang J.Y. Yu B. Peroxisome proliferator-activated receptor-γ Coactivator-1α inhibits vascular calcification through sirtuin 3-mediated reduction of mitochondrial oxidative stress Antioxid Redox Signal 31 2019 75 91 10.1089/ars.2018.7620 30829051
17 Jornayvaz F.R. Shulman G.I. Regulation of mitochondrial biogenesis Essays Biochem 47 2010 69 84 10.1042/bse0470069 20533901
18 Cantó C. Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure Curr Opin Lipidol 20 2009 98 105 10.1097/MOL.0b013e328328d0a4 19276888
19 Ma W.Q. Han X.Q. Wang Y. Wang X. Zhu Y. Liu N.F. Nε-carboxymethyl-lysine promotes calcium deposition in VSMCs via intracellular oxidative stress-induced PDK4 activation and alters glucose metabolism Oncotarget 8 2017 112841 112854 10.18632/oncotarget.22835 29348870
20 Rao J. Li J. Liu Y. The key role of PGC-1α in mitochondrial biogenesis and the proliferation of pulmonary artery vascular smooth muscle cells at an early stage of hypoxic exposure Mol Cell Biochem 367 2012 9 18 10.1007/s11010-012-1313-z 22527940
21 Ma W.Q. Sun X.J. Wang Y. Zhu Y. Han X.Q. Liu N.F. Restoring mitochondrial biogenesis with metformin attenuates β-GP-induced phenotypic transformation of VSMCs into an osteogenic phenotype via inhibition of PDK4/oxidative stress-mediated apoptosis Mol Cell Endocrinol 479 2019 39 53 10.1016/j.mce.2018.08.012 30170182
22 Galli U. Mesenzani O. Coppo C. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2 Eur J Med Chem 55 2012 58 66 10.1016/j.ejmech.2012.07.001 22835719
23 Han L. Zhang Y. Zhang M. Interleukin-1β-induced senescence promotes osteoblastic transition of vascular smooth muscle cells Kidney Blood Press Res 45 2020 314 330 10.1159/000504298 32126555
24 Adebayo M. Singh S. Singh A.P. Dasgupta S. Mitochondrial fusion and fission: the fine-tune balance for cellular homeostasis FASEB J 35 2021 e21620 10.1096/fj.202100067R
25 Hall A.R. Burke N. Dongworth R.K. Hausenloy D.J. Mitochondrial fusion and fission proteins: novel therapeutic targets for combating cardiovascular disease Br J Pharmacol 171 2014 1890 1906 10.1111/bph.12516 24328763
26 McLelland G.L. Goiran T. Yi W. Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy eLife 7 2018 e32866 10.7554/eLife.32866
27 Karbowski M. Arnoult D. Chen H. Chan D.C. Smith C.L. Youle R.J. Quantitation of mitochondrial dynamics by photolabeling of individual organelles shows that mitochondrial fusion is blocked during the Bax activation phase of apoptosis J Cell Biol 164 2004 493 499 10.1083/jcb.200309082 14769861
28 Germain M. Mathai J.P. McBride H.M. Shore G.C. Endoplasmic reticulum BIK initiates DRP1-regulated remodelling of mitochondrial cristae during apoptosis EMBO J 24 2005 1546 1556 10.1038/sj.emboj.7600592 15791210
29 Jadli A. Gomes K. Patel V.B. Pharmacological inhibition of Drp1 dependent mitochondrial fission alleviates mitochondrial dysfunction-associated cell death in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 41 2021 10.1161/atvb.41.suppl_1.p176
30 Kim H. Kim H.J. Lee K. α-lipoic acid attenuates vascular calcification via reversal of mitochondrial function and restoration of Gas6/Axl/Akt survival pathway J Cell Mol Med 16 2012 273 286 10.1111/j.1582-4934.2011.01294.x 21362131
31 Rogers M.A. Maldonado N. Hutcheson J.D. Dynamin-related Protein 1 inhibition attenuates cardiovascular calcification in the presence of oxidative stress Circ Res 121 2017 220 233 10.1161/CIRCRESAHA.116.310293 28607103
32 Wang E.Y. Gang H. Aviv Y. Dhingra R. Margulets V. Kirshenbaum L.A. p53 mediates autophagy and cell death by a mechanism contingent on Bnip3 Hypertension 62 2013 70 77 10.1161/HYPERTENSIONAHA.113.01028 23648705
33 Phadwal K. Tang Q.Y. Luijten I. p53 regulates mitochondrial dynamics in vascular smooth muscle cell calcification Int J Mol Sci 24 2023 1643 10.3390/ijms24021643 36675156
34 Zhu Y. Han X.Q. Sun X.J. Yang R. Ma W.Q. Liu N.F. Lactate accelerates vascular calcification through NR4A1-regulated mitochondrial fission and BNIP3-related mitophagy Apoptosis 25 2020 321 340 10.1007/s10495-020-01592-7 31993850
35 Toyama E.Q. Herzig S. Courchet J. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress Science 351 2016 275 281 10.1126/science.aab4138 26816379
36 Herzig S. Shaw R.J. Shaw R.J. AMPK: guardian of metabolism and mitochondrial homeostasis Nat Rev Mol Cell Biol 19 2018 121 135 10.1038/nrm.2017.95 28974774
37 Chen W.R. Zhou Y.J. Sha Y. Wu X.P. Yang J.Q. Liu F. Melatonin attenuates vascular calcification by inhibiting mitochondria fission via an AMPK/Drp1 signalling pathway J Cell Mol Med 24 2020 6043 6054 10.1111/jcmm.15157 32368857
38 Chen W.R. Zhou Y.J. Yang J.Q. Liu F. Wu X.P. Sha Y. Melatonin attenuates calcium deposition from vascular smooth muscle cells by activating mitochondrial fusion and mitophagy via an AMPK/OPA1 signaling pathway Oxid Med Cell Longev 2020 2020 5298483 10.1155/2020/5298483
39 Pickles S. Vigié P. Youle R.J. Mitophagy and quality control mechanisms in mitochondrial maintenance Curr Biol 28 2018 R170 R185 10.1016/j.cub.2018.01.004 29462587
40 Jin S.M. Lazarou M. Wang C. Kane L.A. Narendra D.P. Youle R.J. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL J Cell Biol 191 2010 933 942 10.1083/jcb.201008084 21115803
41 Yang J.Y. Yang W.Y. Bit-by-bit autophagic removal of parkin-labelled mitochondria Nat Commun 4 2013 2428 10.1038/ncomms3428 24013556
42 Novak I. Kirkin V. McEwan D.G. Nix is a selective autophagy receptor for mitochondrial clearance EMBO Rep 11 2010 45 51 10.1038/embor.2009.256 20010802
43 Zhu Y. Massen S. Terenzio M. Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determines pro-survival mitophagy versus apoptosis J Biol Chem 288 2013 1099 1113 10.1074/jbc.M112.399345 23209295
44 Verissimo T. Faivre A. Rinaldi A. Decreased Renal Gluconeogenesis Is a Hallmark of Chronic Kidney Disease J Am Soc Nephrol 33 2022 810 827 10.1681/ASN.2021050680 35273087
45 Zhu Y. Zhang J.L. Yan X.J. Ji Y. Wang F.F. Exploring a new mechanism between lactate and VSMC calcification: PARP1/POLG/UCP2 signaling pathway and imbalance of mitochondrial homeostasis Cell Death Dis 14 2023 598 10.1038/s41419-023-06113-3 37679327
46 Kleele T. Rey T. Winter J. Distinct fission signatures predict mitochondrial degradation or biogenesis Nature 593 2021 435 439 10.1038/s41586-021-03510-6 33953403
47 Shin J.H. Ko H.S. Kang H. Paris (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease Cell 144 2011 689 702 10.1016/j.cell.2011.02.010 21376232
48 Zhu Y. Ji J.J. Yang R. Lactate accelerates calcification in VSMCs through suppression of BNIP3-mediated mitophagy Cell Signal 58 2019 53 64 10.1016/j.cellsig.2019.03.006 30851408
49 Toita R. Otani K. Kawano T. Fujita S. Murata M. Kang J.H. Protein kinase A (PKA) inhibition reduces human aortic smooth muscle cell calcification stimulated by inflammatory response and inorganic phosphate Life Sci 209 2018 466 471 10.1016/j.lfs.2018.08.051 30144450
50 Yang M. Chadwick A.E. Dart C. Kamishima T. Quayle J.M. Bioenergetic profile of human coronary artery smooth muscle cells and effect of metabolic intervention PLoS One 12 2017 e0177951 10.1371/journal.pone.0177951
51 Heuschkel M.A. Babler A. Heyn J. Distinct role of mitochondrial function and protein kinase C in intimal and medial calcification in vitro Front Cardiovasc Med 9 2022 959457 10.3389/fcvm.2022.959457
52 Shi J. Yang Y. Cheng A. Xu G. He F. Metabolism of vascular smooth muscle cells in vascular diseases Am J Physiol Heart Circ Physiol 319 2020 H613 H631 10.1152/ajpheart.00220.2020 32762559
53 Chen J. Yu H. Tan X. PFKFB3-driven vascular smooth muscle cell glycolysis promotes vascular calcification via the altered FoxO3 and lactate production FASEB J 37 2023 e23182 10.1096/fj.202300900R
54 Zhu Y. Ji J.J. Wang X.D. Periostin promotes arterial calcification through PPARγ-related glucose metabolism reprogramming Am J Physiol Heart Circ Physiol 320 2021 H2222 H2239 10.1152/ajpheart.01009.2020 33834866
55 Rashdan N.A. Sim A.M. Cui L. Osteocalcin regulates arterial calcification via altered Wnt signaling and glucose metabolism J Bone Miner Res 35 2020 357 367 10.1002/jbmr.3888 31596966
56 Lee S.J. Jeong J.Y. Oh C.J. Pyruvate dehydrogenase kinase 4 promotes vascular calcification via SMAD1/5/8 phosphorylation Sci Rep 5 2015 16577 10.1038/srep16577
57 Ma W.Q. Sun X.J. Zhu Y. Liu N.F. PDK4 promotes vascular calcification by interfering with autophagic activity and metabolic reprogramming Cell Death Dis 11 2020 991 10.1038/s41419-020-03162-w 33203874
58 Kendrick J. Chonchol M. The role of phosphorus in the development and progression of vascular calcification Am J Kidney Dis 58 2011 826 834 10.1053/j.ajkd.2011.07.020 21956015
59 Alesutan I. Moritz F. Haider T. Impact of β-glycerophosphate on the bioenergetic profile of vascular smooth muscle cells J Mol Med (Berl) 98 2020 985 997 10.1007/s00109-020-01925-8 32488546
60 Espitia O. Chatelais M. Steenman M. Implication of molecular vascular smooth muscle cell heterogeneity among arterial beds in arterial calcification PLoS One 13 2018 e0191976 10.1371/journal.pone.0191976
61 Shi J. Yang Y. Wang Y.N. Oxidative phosphorylation promotes vascular calcification in chronic kidney disease Cell Death Dis 13 2022 229 10.1038/s41419-022-04679-y 35277475
62 Lin X. Shan S.K. Xu F. The crosstalk between endothelial cells and vascular smooth muscle cells aggravates high phosphorus-induced arterial calcification Cell Death Dis 13 2022 650 10.1038/s41419-022-05064-5 35882857
63 Uto K. Yoshizawa S. Aoki C. Nishikawa T. Oda H. Inhibition of extracellular matrix integrity attenuates the early phase of aortic medial calcification in a rodent model Atherosclerosis 319 2021 10 20 10.1016/j.atherosclerosis.2020.12.015 33453491
64 Papa S. Martino P.L. Capitanio G. The oxidative phosphorylation system in mammalian mitochondria Adv Exp Med Biol 942 2012 3 37 10.1007/978-94-007-2869-1_1 22399416
65 Tirichen H. Yaigoub H. Xu W. Wu C. Li R. Li Y. Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress Front Physiol 12 2021 627837 10.3389/fphys.2021.627837
66 Mailloux R.J. An update on mitochondrial reactive oxygen species production Antioxidants (Basel) 9 2020 472 10.3390/antiox9060472 32498250
67 Jastroch M. Divakaruni A.S. Mookerjee S. Treberg J.R. Brand M.D. Mitochondrial proton and electron leaks Essays Biochem 47 2010 53 67 10.1042/bse0470053 20533900
68 Tbahriti H.F. Kaddous A. Bouchenak M. Mekki K. Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients Biochem Res Int 2013 2013 358985 10.1155/2013/358985
69 Daenen K. Andries A. Mekahli D. Van Schepdael A. Jouret F. Bammens B. Oxidative stress in chronic kidney disease Pediatr Nephrol 34 2019 975 991 10.1007/s00467-018-4005-4 30105414
70 Huang M. Zheng L. Xu H. Oxidative stress contributes to vascular calcification in patients with chronic kidney disease J Mol Cell Cardiol 138 2020 256 268 10.1016/j.yjmcc.2019.12.006 31866376
71 Watanabe S. Fujii H. Kono K. Watanabe K. Goto S. Nishi S. Influence of oxidative stress on vascular calcification in the setting of coexisting chronic kidney disease and diabetes mellitus Sci Rep 10 2020 20708 10.1038/s41598-020-76838-0
72 Chang J.F. Liu S.H. Lu K.C. Uremic vascular calcification is correlated with oxidative elastic lamina injury, contractile smooth muscle cell loss, osteogenesis, and apoptosis: the human pathobiological evidence Front Med (Lausanne) 7 2020 78 10.3389/fmed.2020.00078 32266272
73 Huang L.H. Sun X.Y. Ouyang J.M. Shape-dependent toxicity and mineralization of hydroxyapatite nanoparticles in A7R5 aortic smooth muscle cells Sci Rep 9 2019 18979 10.1038/s41598-019-55428-9
74 Nguyen N.T. Nguyen T.T. Da Ly D. Oxidative stress by Ca2+ overload is critical for phosphate-induced vascular calcification Am J Physiol Heart Circ Physiol 319 2020 H1302 H1312 10.1152/ajpheart.00305.2020 33095057
75 Thi Nguyen N. Thi Nguyen T. Nguyen H.T. Inhibition of mitochondrial phosphate carrier prevents high phosphate-induced superoxide generation and vascular calcification Exp Mol Med 55 2023 532 540 10.1038/s12276-023-00950-0 36854772
76 Nguyen N.T. Nguyen T.T. Park K.S. Oxidative stress related to plasmalemmal and mitochondrial phosphate transporters in vascular calcification Antioxidants (Basel) 11 2022 494 10.3390/antiox11030494 35326144
77 Balogh E. Tóth A. Méhes G. Trencsényi G. Paragh G. Jeney V. Hypoxia triggers osteochondrogenic differentiation of vascular smooth muscle cells in an HIF-1 (hypoxia-inducible factor 1)-dependent and reactive oxygen species-dependent manner Arterioscler Thromb Vasc Biol 39 2019 1088 1099 10.1161/ATVBAHA.119.312509 31070451
78 Meng J. Lv Z. Zhang Y. Precision redox: the key for antioxidant pharmacology Antioxid Redox Signal 34 2021 1069 1082 10.1089/ars.2020.8212 33270507
79 Zhang M. Li T. Tu Z. Both high glucose and phosphate overload promote senescence-associated calcification of vascular muscle cells Int Urol Nephrol 54 2022 2719 2731 10.1007/s11255-022-03195-4 35396645
80 Ebert T. Pawelzik S.C. Witasp A. Inflammation and premature ageing in chronic kidney disease Toxins (Basel) 12 2020 227 10.3390/toxins12040227 32260373
81 Xu D. Zeng F. Han L. The synergistic action of phosphate and interleukin-6 enhances senescence-associated calcification in vascular smooth muscle cells depending on p53 Mech Ageing Dev 182 2019 111124 10.1016/j.mad.2019.111124
82 Mackenzie N.C.W. MacRae V.E. The role of cellular senescence during vascular calcification: a key paradigm in aging research Curr Aging Sci 4 2011 128 136 10.2174/1874609811104020128 21235497
83 Sanchis P. Ho C.Y. Liu Y. Arterial ‘inflammaging’ drives vascular calcification in children on dialysis Kidney Int 95 2019 958 972 10.1016/j.kint.2018.12.014 30827513
84 Docherty C.K. Strembitska A. Baker C.P. Schmidt F.F. Reay K. Mercer J.R. Inducing energetic switching using klotho improves vascular smooth muscle cell phenotype Int J Mol Sci 23 2021 217 10.3390/ijms23010217 35008643
85 Villa-Bellosta R. Rivera-Torres J. Osorio F.G. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment Circulation 127 2013 2442 2451 10.1161/CIRCULATIONAHA.112.000571 23690466
86 Sahin E. Colla S. Liesa M. Telomere dysfunction induces metabolic and mitochondrial compromise Nature 470 2011 359 365 10.1038/nature09787 21307849
87 Li S. Zhan J.K. Wang Y.J. Exosomes from hyperglycemia-stimulated vascular endothelial cells contain versican that regulate calcification/senescence in vascular smooth muscle cells Cell Biosci 9 2019 1 10.1186/s13578-018-0263-x 30622695
88 Li X. Liu A. Xie C. The transcription factor GATA6 accelerates vascular smooth muscle cell senescence-related arterial calcification by counteracting the role of anti-aging factor SIRT6 and impeding DNA damage repair Kidney Int 105 2024 115 131 10.1016/j.kint.2023.09.028 37914087
89 Benz K. Varga I. Neureiter D. Vascular inflammation and media calcification are already present in early stages of chronic kidney disease Cardiovasc Pathol 27 2017 57 67 10.1016/j.carpath.2017.01.004 28171827
90 Machado S.E. Spangler D. Black L.M. Traylor A.M. Balla J. Zarjou A. A reproducible mouse model of moderate CKD with early manifestations of osteoblastic transition of cardiovascular system Front Physiol 13 2022 897179 10.3389/fphys.2022.897179
91 Xu C. Smith E.R. Tiong M.K. Ruderman I. Toussaint N.D. Interventions to attenuate vascular calcification progression in chronic kidney disease: a systematic review of clinical trials J Am Soc Nephrol 33 2022 1011 1032 10.1681/ASN.2021101327 35232774
92 Wen W. Portales-Castillo I. Seethapathy R. Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients-a systematic review and meta-analysis Nephrol Dial Transplant 38 2023 733 745 10.1093/ndt/gfac171 35521751
93 Feng W. Teng Y. Zhong Q. Biomimetic grapefruit-derived extracellular vesicles for safe and targeted delivery of sodium thiosulfate against vascular calcification ACS Nano 17 2023 24773 24789 10.1021/acsnano.3c05261 38055864
94 Subhash N. Sriram R. Kurian G.A. Sodium thiosulfate protects brain in rat model of adenine induced vascular calcification Neurochem Int 90 2015 193 203 10.1016/j.neuint.2015.09.004 26363090
95 Xu T.H. Qiu X.B. Sheng Z.T. Restoration of microRNA-30b expression alleviates vascular calcification through the mTOR signaling pathway and autophagy J Cell Physiol 234 2019 14306 14318 10.1002/jcp.28130 30701530
96 Mori D. Matsui I. Shimomura A. Protein carbamylation exacerbates vascular calcification Kidney Int 94 2018 72 90 10.1016/j.kint.2018.01.033 29716796
97 Hou X. Li Z. Higashi Y. Delafontaine P. Sukhanov S. Insulin-like growth factor I prevents cellular aging via activation of mitophagy J Aging Res 2020 2020 4939310
98 Sasaki Y. Ikeda Y. Uchikado Y. Akasaki Y. Sadoshima J. Ohishi M. Estrogen plays a crucial role in Rab9-dependent mitochondrial autophagy, delaying arterial senescence J Am Heart Assoc 10 2021 e019310
99 Cui L. Zhou Q. Zheng X. Sun B. Zhao S. Mitoquinone attenuates vascular calcification by suppressing oxidative stress and reducing apoptosis of vascular smooth muscle cells via the Keap1/Nrf2 pathway Free Radic Biol Med 161 2020 23 31 33011276
100 Liu S.M. Zhang Y.R. Chen Y. Intermedin alleviates vascular calcification in CKD through Sirtuin 3-mediated inhibition of mitochondrial oxidative stress Pharmaceuticals (Basel) 15 2022 1224 36297336
101 Byun K.A. Oh S. Yang J.Y. Lee S.Y. Son K.H. Byun K. Ecklonia cava extracts decrease hypertension-related vascular calcification by modulating PGC-1α and SOD2 Ecklonia Biomed Pharmacother 153 2022 113283
102 Nelson A.J. Raggi P. Wolf M. Gold A.M. Chertow G.M. Roe M.T. Targeting vascular calcification in chronic kidney disease JACC Basic Transl Sci 5 2020 398 412 32368697
